Hazard ratio for in-hospital mortality amongst hospitalized patients in NYC were not significantly different for those given HCQ

Odds of cardiac arrest were higher in hospitalized patients in NYC given HCQ

Odds of abnormal ECG findings were higher in hospitalized patients in NYC given HCQ

From multinational registry of patients hospitalized between 12/20/19 and 4/14/20, individuals treated with HCQ had a higher risk of in-hospital mortality compared to an untreated control group

From multinational registry of patients hospitalized between 12/20/19 and 4/14/20, individuals treated with HCQ had a higher risk of clinically significant ventricular arrhythmia compared to an untreated control group

Hydroxychloroquine did not substantially reduce symptom severity in patients with early or mild COVID-19.

As of now no randomized clinical trials reported have shown a positive correlation to COVID-19 recovery through the use of hydroxychloroquine

A small randomized trial in Shanghai, China by Chen J, Liu D, Liu L, et al. revealed that by day 7, a total of 86% of the patients in the HCQ-treated group and 93% of those in the control group had negative results on viral throat swabs

Researchers who used a randomized, double-blind, placebo-controlled study found no significant difference between new illness and symptoms compatible with COVID-19 infection in the hydroxychloroquine sulfate and placebo groups (11.8% and 14.3%, respectively).

A study including 176 hospitals in the UK showed no significant difference between COVID-19 patients who received hydroxychloroquine and those who received usual care alone.